As of May 26
| -0.015 / -3.00%|
The 3 analysts offering 12-month price forecasts for Arch Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 1.60. The median estimate represents a +518.56% increase from the last price of 0.49.
The current consensus among 3 polled investment analysts is to Buy stock in Arch Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.